Kovaltry 500 Unit (Antihemophilic Factor (Recombinant) KIT) 500 UNIT

KOVALTRY 500 Unit is a recombinant antihemophilic factor used to manage bleeding episodes in hemophilia A. This intravenous kit helps replace clotting factor VIII for effective bleeding control.

Strength

500 UNIT

Pack Size

2.5ML

Manufacturer / TM Owner

BAYER INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

KOVALTRY 500 Unit is primarily used to treat and prevent bleeding episodes in individuals with hemophilia A. This condition is characterized by a deficiency in clotting factor VIII, leading to prolonged bleeding. The medication works by replacing the missing factor, helping the blood to clot properly. It is often administered intravenously to manage bleeding episodes, control surgical bleeding, and for routine prophylaxis to prevent bleeding in individuals with hemophilia A.

Side Effects

Common effects of KOVALTRY 500 Unit may include mild reactions at the injection site, such as redness or swelling. Some individuals might experience allergic reactions, which can range from mild to severe. It is important to monitor for any signs of an allergic reaction and seek medical attention if necessary.

Precautions & Warnings

KOVALTRY 500 Unit should be handled with care and stored as directed to maintain its effectiveness. It is crucial to follow the administration instructions provided by a healthcare professional. Individuals with known allergies to any components of the medication should avoid its use. Always consult a healthcare provider before starting any new medication.

Avoid Interactions

KOVALTRY 500 Unit may interact with certain medications, including those that affect blood clotting. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other substances that affect blood clotting should be used with caution.

Frequently Asked Questions

KOVALTRY 500 Unit is used to manage and prevent bleeding episodes in individuals with hemophilia A by replacing the missing clotting factor VIII.

KOVALTRY 500 Unit is administered intravenously, typically by a healthcare professional, to ensure proper dosing and administration.

Common side effects may include mild reactions at the injection site, such as redness or swelling, and allergic reactions.

KOVALTRY 500 Unit is specifically designed for the treatment of hemophilia A and should not be used for other types of bleeding disorders without medical advice.

KOVALTRY 500 Unit should be stored as directed on the packaging, typically in a refrigerator, to maintain its effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.